This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lisukov, I A Articles by Kozlov, V A Search for Related Content PubMed PubMed Citation Articles by Lisukov, I A Articles by Kozlov, V A Social Bookmarking                   What's this?

High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus

Novosibirsk State Medical Academy, Novosibirsk, Russia, depsct{at}online.nsk.su

S A Sizikova

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

A D Kulagin

Novosibirsk State Medical Academy, Novosibirsk, Russia

I V Kruchkova

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

A V Gilevich

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

L P Konenkova

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

E V Zonova

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

E R Chernykh

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

O Y Leplina

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

T N Sentyakova

Novosibirsk State Medical Academy, Novosibirsk, Russia

A A Demin

Novosibirsk State Medical Academy, Novosibirsk, Russia

V A Kozlov

Institute of Clinical Immunology RAMS SB, Novosibirsk, Russia

Systemic lupus erythematosus(SLE) is an immune-mediateddisease that is responsiveto suppression or modulation of the immune system. Patients with SLE who experience persistent multiorgan dysfunction, despite standard doses of intravenous cyclophosphamide (Cy), represent a subset of patients at high risk of early death. We investigated the efficacy and toxicity of high-dose immunosuppression and autologous hematopoietic stem cell transplantation (SCT) to treat such patients. Six patients (all female, age 15-29 years) with severe refractory SLE were enrolled in the clinic of our institution from 1998 to 2003. All patients were seriously ill, with SLE disease activity indices (SLEDAI) of 6-30, includingtwo cases with central nervoussystem lupus, one case with lung vasculitis, and three cases with nephritis and nephrotic syndrome. All patients were registered in the European Group for Blood and Marrow Transplantation (EBMT)/European League Against Rheumatism (EULAR) database. Previous immunosuppression included pulse Cy intravenous, prednisolone (standard doses and pulse therapy), oral Cy and azathioprine, with little or no effect on disease progression.Autologous hemopoietic stem cells were collected from bone marrow (n 4) or mobilized from peripheral blood with Cy and granulocyte colony-stimulating factor (G-CSF) (n 2). Pre-transplant conditioning regimens included BEAM + ATG (n 2), melphalan 140 mg/m² etoposid 1600 mg/m² (n 2) and Cy 200 mg/kg + ATG (n 2). Median time to an absolute neutrophil count (ANC) greater than 0.5 x10 50 x10 ⁹/L and platelet count greater than ⁹/L was 13 and 15 days, respectively. Three patients died on days 11, 22 and 63 due to transplant-relatedcomplications. The follow-up is now 60 and six months for two patients (complete remission), and 42 months for one other patient (partial response). All patients had experienced multiple and severe episodes of infections pre-SCT and long-term history of corticosteroid therapy (3-14 years). We conclude that achievement of prolonged, corticosteroid-freeremissions is a reality. Judicious selection of patients earlier in disease or in remission, but with a high risk of relapse or further progression, will diminish transplantation-relatedmortality.

Key Words: stem cell transplantation • systemic lupus erythematosus

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?